sonic hedgehog

sonic hedgehog
screenshot by User:Peter Znamenskiy, structure from Hall, T.M., Porter, J.A., · Public domain · source
Name	Sonic hedgehog
Locus	7q36.3
Organism	Human
Refseq	NM_000193
Protein	Sonic hedgehog protein
Family	Hedgehog family

sonic hedgehog

Sonic hedgehog is a developmental signaling molecule encoded by the human SHH gene that acts as a morphogen during embryogenesis. It participates in patterning of the neural tube, limbs, and craniofacial structures through concentration-dependent signaling, interacting with receptors and downstream effectors to regulate cell fate, proliferation, and differentiation. SHH signaling is conserved across metazoans and has been studied in model organisms and clinical contexts including congenital malformations and cancer.

Introduction

SHH is a member of the Hedgehog (gene family) family alongside Indian hedgehog and Desert hedgehog, discovered in genetic and embryologic screens that included work in Drosophila melanogaster and vertebrate systems such as Mus musculus and Danio rerio. Landmark studies linking SHH to human disease involved researchers at institutions like Harvard University, University of Cambridge, and Cold Spring Harbor Laboratory and appeared in journals including Nature and Cell. The pathway includes core components characterized in the laboratories of Philip A. Beachy, Chiang C., and Kristian Helin, and has connections to broader developmental paradigms explored by investigators at Max Planck Society and Howard Hughes Medical Institute.

Gene and Protein Structure

The SHH locus at chromosomal band 7q36 spans regulatory domains studied using comparative genomics across species including Mus musculus and Gallus gallus. The SHH preproprotein undergoes autocatalytic cleavage and dual lipid modification producing an N-terminal signaling fragment (SHH-N) that is palmitoylated and cholesterol-modified, a biochemical mechanism elucidated in biochemical work from Stanford University and Massachusetts Institute of Technology. Structural biology studies using techniques developed at European Molecular Biology Laboratory and Max Planck Institute for Biophysical Chemistry resolved interactions between SHH-N and the receptor Patched1 (PTCH1), clarifying contact residues and lipid-dependent presentation. Mutational analyses reported in contributions from Johns Hopkins University and University of California, San Francisco mapped functional domains critical for receptor binding and gradient formation.

Expression and Regulation

SHH expression is tightly regulated by distant cis-regulatory elements, enhancers, and chromatin architecture studied with methods from Broad Institute and Wellcome Trust Sanger Institute. Forebrain expression domains include the prechordal plate and ventral neural tube, with limb expression in the zone of polarizing activity (ZPA) identified in classic grafting experiments by researchers at University of Cambridge and University of Oregon. Transcriptional control involves factors such as GLI family members characterized at University of California, Berkeley and signaling crosstalk with pathways investigated at Yale University and University of Pennsylvania. Long-range enhancer perturbations in clinical cohorts from Boston Children's Hospital and Great Ormond Street Hospital revealed phenotypes arising from regulatory disruption.

Developmental Roles and Mechanisms

SHH functions as a morphogen to pattern the anterior–posterior axis of the limb bud and dorsal–ventral axis of the neural tube, with concentration- and time-dependent effects demonstrated in experimental systems at Salk Institute and Max Planck Institute for Developmental Biology. The pathway signals via PTCH1 relief of inhibition on the transmembrane protein Smoothened (SMO), culminating in regulation of GLI transcription factors; these mechanistic steps were dissected using genetic tools from The Rockefeller University and Columbia University. SHH influences proliferation of cerebellar progenitors in the external granule layer, a process characterized in studies from National Institutes of Health and Cold Spring Harbor Laboratory. Feedback regulation, receptor dynamics, and extracellular distribution involving heparan sulfate proteoglycans were elucidated through collaborations among laboratories at University of Oxford, Karolinska Institute, and EMBL-EBI.

Clinical Significance and Disorders

Pathogenic variants in SHH or its regulatory landscape cause congenital anomalies such as holoprosencephaly and preaxial polydactyly; clinical genetics reports from Mayo Clinic and Great Ormond Street Hospital document genotype–phenotype correlations. Aberrant activation of SHH signaling contributes to oncogenesis in medulloblastoma and basal cell carcinoma, with translational studies at Dana-Farber Cancer Institute, MD Anderson Cancer Center, and Sloan Kettering Cancer Center linking pathway mutations to tumor subtypes. Therapeutic resistance and secondary mutations in components like SMO have been reported in clinical trials led by investigators at National Cancer Institute and pharmaceutical collaborations with companies such as Genentech and Novartis.

Research Tools and Therapeutic Applications

Experimental tools include recombinant SHH-N ligand, GLI reporter assays developed at Addgene and gene-editing approaches using CRISPR-Cas9 platforms from Broad Institute and MIT to model pathway perturbation. Small-molecule modulators such as vismodegib and sonidegib emerged from drug discovery programs at Genentech and Sun Pharmaceutical Industries and are used in trials coordinated by European Medicines Agency and U.S. Food and Drug Administration regulated studies. Regenerative medicine efforts at Bill & Melinda Gates Foundation-funded consortia and stem cell centers like Stanford School of Medicine and University College London explore SHH modulation for tissue repair, while high-throughput screens at Biogen and academic cores refine pathway-targeted chemotypes.

Category:Human genes Category:Developmental biology